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A B S T R A C T
Expression of abnormally long polyglutamine (polyQ) tracks is the source of a range of dominant neurode-
generative diseases, such as Huntington disease. Currently, there is no treatment for this devastating disease,
although some chemicals, e.g., metformin, have been proposed as therapeutic solutions. In this work, we show
that metformin, together with salicylate, can synergistically reduce the number of aggregates produced after
polyQ expression in Caenorhabditis elegans. Moreover, we demonstrate that incubation polyQ-stressed worms
with low doses of both chemicals restores neuronal functionality. Both substances are pleitotropic and may
activate a range of different targets. However, we demonstrate in this report that the beneficial effect induced by
the combination of these drugs depends entirely on the catalytic action of AMPK, since loss of function mutants
of aak-2/AMPKα2 do not respond to the treatment. To further investigate the mechanism of the synergetic
activity of metformin/salicylate, we used CRISPR to generate mutant alleles of the scaffolding subunit of AMPK,
aakb-1/AMPKβ1. In addition, we used an RNAi strategy to silence the expression of the second AMPKβ subunit
in worms, namely aakb-2/AMPKβ2. In this work, we demonstrated that both regulatory subunits of AMPK are
modulators of protein homeostasis. Interestingly, only aakb-2/AMPKβ2 is required for the synergistic action of
metformin/salicylate to reduce polyQ aggregation. Finally, we showed that autophagy acts downstream of
metformin/salicylate-related AMPK activation to promote healthy protein homeostasis in worms.
1. Introduction
Several late-onset neurodegenerative diseases are caused by ab-
normal microsatellite expansions of CAG repeats, which encode tracts
of polyglutamines (polyQs) (reviewed in Paulson [1]). These expan-
sions lay within encoding regions of at least nine endogenous genes,
which have unrelated functions (see for a review [2]). For example,
HTT encodes huntingtin, a protein of unknown function that causes
Huntington disease (HD) when more than 35 CAG triplets are present
[3]. Other diseases caused by polyQ repeats include six of the spino-
cerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17), dentatorubral-pallido-
luysian atrophy (DRPLA), and spino-bulbar muscular atrophy (SBMA)
[1]. The causative genes of the diseases encode proteins with different
functions that vary from mRNA translation and RNA regulation to
ubiquitin-proteasome function (ataxin-1 and ataxin-3 [4,5]). These
molecules, which have important roles within cells, become gain-of-
function toxic proteins when expansions of polyQs go beyond a pa-
thological threshold [6]. These mutant proteins become unstable and
show a tendency to misfold and, as a consequence, become very prone
to aggregation. Therefore, the hallmark of all these diseases is the
presence of aggregates, and eventually, inclusion bodies (IB), which
include the mutant protein but also unrelated proteins sequestered
within [7]. The fact that the same source of toxicity (i.e., polyQ ex-
pansions within endogenous proteins) produces different diseases may
be related to the distinct expression patterns of these genes, which
produce malfunction in different neuronal types [2].
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Caenorhabditis elegans is a genetically tractable model, which has
been widely used to study polyQ toxicity (see for example [8–10]).
Worms expressing polyQs in different tissues helped to uncover many
genes modulating the rate of aggregation and/or the toxicity induced
by these molecules [8,11–14]. Using neuronal and muscular models of
polyQ toxicity in C. elegans, we described AMP-activated protein kinase
(AMPK) as a good candidate to manipulate aggregation and toxicity
induced by these molecules [15,16]. Moreover, AMPK activation is
neuroprotective in in vivo mouse models of HD [15–17].
AMPK is an obligate heterotrimer enzyme composed of a catalytic
subunit (AMPKα) and two regulatory subunits (AMPKβ and AMPKγ).
AMPK is a master regulator of energy and metabolism in cells [18]. In
addition, this enzyme can react to different types of stress of a different
nature, e.g., polyQ-induced toxicity [15–17]. The regulation of AMPK
function is very complex. When ATP levels are low, the concentration of
AMP rises, and this molecule binds to AMPKγ, a regulatory subunit of
this enzyme, which in turn activates the catalytic subunit (AMPKα) of
the complex, inducing the phosphorylation of several targets (reviewed
by Kim et al. [19],). In addition to AMP, AMPK is activated by a ple-
thora of metabolites, protein kinases, and synthetic compounds [19].
Among the synthetic activators, metformin is widely accepted to be a
classic indirect activator of this enzyme [19]. This compound, which is
widely used to treat type 2 diabetes, induces a mild inhibition of
complex I of the electron transport chain in the mitochondria. Non-
lethal mild inhibition of this complex increases AMP levels, which in
turn activates AMPK.
Interestingly, metformin can reduce polyQ-induced aggregation in
muscle cells and neuronal toxicity in C. elegans [15,16] and reduce
behavioural phenotypes in mammalian models of HD [15–17,20,21].
Metformin has also beneficial effects when administered in HD patients.
In this regard, we have analysed the so-called Enroll-HD database,
which included at the time more than 8000 HD patients and healthy
controls. Through this analysis, we demonstrated that HD patients who
were also type 2 diabetics and were taking metformin to treat this
condition, showed better marks in cognitive tests, compared to non-
diabetic HD patients [22]. Another well-known modulator of AMPK
activity is salicylate, which binds to AMPKβ (scaffolding subunit) to
induce activation of the complex [19]. Some studies have shown that
both compounds, metformin and salicylate, are able to activate AMPK
in a synergistic way to improve insulin resistance [23]. Moreover, in-
cubating cells with combinations of aspirin and metformin enhances
apoptosis in in vitro models of breast cancer [24]. However, both sub-
stances act pleiotropically and therefore AMPK is not their only target.
For example, it has been shown that metformin protects from cancer by
indirect activation of AMPK, inhibition of Hexokinase II and suppres-
sion of gluconeogenesis, through inhibition of glycerol-3-phosphate
dehydrogenase [25]. Moreover, metformin can also alter glucose
transport and enhances HIF1A (Hipoxia Inducible Factor 1 Subunit
Alpha) degradation [25]. In murine models of atherosclerosis it is
protective by activation of AMPK, reducing the expression of AT1R
(type 1 Angiotensin II Receptor) and increasing the expression of SOD1
(Superoxide dismutase 1) [26]. Salicylate shows also complex mod-
ulation of targets, different than AMPK. It is well-known that salicylate
is able to promote the acetylation and inhibition of cyclooxygenases to
reduce inflammation [27]. This substance is chemoprotective against
colorectal cancer through acetylation of cellular cyclins (CDKs) [28],
and it does suppress nuclear translocation of HsGAPDH preventing cell
death [29]. Those are a few examples of the different nature of targets
modulated by metformin and/or salicylate. In this work, we show that
synergistic activation of AMPK, using low doses of metformin and sal-
icylate, can reduce polyQ aggregation and neuronal impairment in C.
elegans models of polyQ toxicity. Moreover, we show that metformin/
salicylate synergy is dependent exclusively on AMPK. We also report
that the benefitial effects produced by both drugs require a functional
autophagy pathway.
2. Material and methods
2.1. Maintenance of C.elegans strains
All worm strains were maintained at 20 °C degrees as described
elsewhere [30]. N2 standard wild type [30], AM141: rmIs133[unc-
54p::40Q::YFP] X [8] and NL5901: pkIs2386[unc-54p::alphasynuclei-
n::YFP + unc-119(+)] IV [31] strains were obtained from the Cae-
norhabditis Genetics Center (CGC, Minneapolis, MN, USA). The strains
RVM131: vltEx131[mec-3p::112Q::TdTomato; myo-2p::GFP], RVM132:
vltEx131[mec-3p::112Q::TdTomato; myo-2p::GFP]; aak-2(ok524) X, and
RVM137: rmIs133[unc-54p::40Q::YFP] X; aak-2(ok524) X were de-
scribed elsewhere [16]. In this work we have developed the following
strains: RVM301: aakb-1(vlt18) X; RVM304: vltEx131[mec-
3p::112Q::TdTomato; myo-2p::GFP]; aakb-1(vlt18) X; and RVM305:
rmIs133[unc-54p::40Q::YFP] X; aakb-1(vlt18) X. All strains were out-
crossed at least three times.
2.2. Generation of knock-out worms using CRISPR/Cas9 system
CRISPR/Cas9 was used to generate a knock-out in aakb-1 gene. We
based our design and strategy on a modified protocol from the Ceron’s
Lab (IDIBELL Institute, Barcelona, Spain) [32]. We used Alt-R™ S.p.
Cas9 Nuclease 3NLS, and three RNAs to produce two gRNAs: Alt-R™
CRISPR-Cas9 tracrRNA and two AltR™ CRISPR-Cas9 crRNA from In-
tegrated DNA Technologies (IDT DNA, Coralville, IA, USA). The gene
dpy-10 was also disrupted as a selection marker, as described elsewhere
[33]. The guide RNA sequences designed to target aakb-1 were: 5ʹ-ACG
AGC TTG GAA TTC CAC CG-3ʹ and 5ʹ-AGA GGC TAA ATC CTT GTC GA-
3ʹ. The RNA was resuspended in 20 μl of Nuclease-free Duplex Buffer
from IDT DNA. The final concentrations of the CRISPR components
were: Alt-R™ S.p. Cas9 Nuclease 3NLS: 4.5 μM; Alt-R™ CRISPR-Cas9
tracrRNA: 32 μM; target gene AltR™ CRISPR-Cas9 crRNA: 35 μM.
2.3. RNA interference
Worms were fed with E. coli strain HT115 expressing dsRNA of aakb-
2, atg-18, bec-1 and lgg-1 genes into the pL4440 plasmid. A coding
fragment of each gene was amplified using the Phusion high fidelity
polymerase (Thermo Fisher Scientific, Waltham, MA, USA) and the
following primers: FRW_aakb-2: 5ʹ- GGC AAC AAT CAG TCT GGA GG-
3ʹ; REV_aakb-2: 5ʹ-TAC CAT CGG GAT CCG CGT CTG C-3ʹ; FRW_atg-18:
5´- CAC ACT GAC ATA TGA AGG CG-3´; REV_atg-18: 5´-AAG AGA TGA
ACA GAT CCA GTG-3. FRW_bec-1: 5´-TGT GCT TCC ACA TTT GGG TTG
ATG-3´; REV_bec-1: 5´-AGC CAT TGC ACG AGT CCA TCG-3´; FRW_lgg-1:
5ʹ-GAA TCA AAA TGA AGT GGG CTT AC-3ʹ; REV_lgg-1: 5ʹ-TCC TTC TTT
TCG ACC TCT CCT CC-3ʹ.. PCR products were cloned into an EcoRV site
of the pL4440 plasmid to generate RNAi vectors: pJB1_pL4440-lgg-1,
pJB2_ pL4440-aakb-2, pJB3_pL4440-bec-1 and pJB4_pL4440-atg-18. All
vectors, including the empty vector pL4440, were grown overnight at
37 °C in Luria-Bertani liquid medium containing 50 μg/mL carbenicillin
to select positive colonies. We added 1 mM IPTG into grown feeding
bacteria cultures and incubated for 2 h at 37 °C and shaking before
seeding RNAi plates. This induction step allowed us to intensify RNAi
effect in worms. Autophagy-related genes are essential for appropriate
worm development so we induced the knock down expression after L3
stage, to avoid inducing developmental arrest of the worms. Feeding
worms with the E. coli strain HT115 has been shown to change the
expression of the promoter of the muscular unc-54/myosin gene [34].
This is the promoter that drives the expression of the polyQ construct in
muscle cells. If the expression of the polyQs is reduced, then we would
observe and artefactual reduction of the aggregation process, which is
heavily influenced by the concentration of the polyQs. To avoid this, we
also induced RNAi against non-lethal genes in L3 larvae. Therefore,
synchronized populations were incubated in feeding RNAi plates to
induce aakb-2, atg-18, bec-1 and lgg-1 silencing. We scored the number
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of polyQ aggregates after silencing for 24 h.
2.4. Pharmacological assays
To treat worms in liquid culture, synchronized L1 animals were
incubated in 50 mL conical tubes with a final volume of 5 mL, which
contained E. coli strain OP50 as a source of food (OD600 = 0.5), 50 μg/
mL streptomycin, 12.5 μg/mL nystatin, 5 μg/mL cholesterol, and the
specific amount of drug or vehicle, using M9 1X buffer as solvent. L1
animals were treated with several doses of metformin (Sigma-Aldrich-
Merck, St. Louis, MO, USA) and/or salicylate (Sigma-Aldrich-Merck)
until they reached the young adult stage. Then, we scored the number
of polyQ aggregates on the 40Q::YFP worms, and assayed the touch
response on 112Q::TdTom animals. We also investigated the motor
performance of worms expressing 40Q::YFP in muscle cells (see below).
To evaluate whether the treatments (metformin, salicylate and both)
could have an effect on already formed aggregates, we treated
40Q::YFP young adult animals and scored the number of polyQ ag-
gregates in 2-day-old adults. Worms expressing the α-synuclein con-
struct show a late aggregation pattern so we treated young adult ani-
mals, which do not show any signs of aggregation, and scored the
number of α-syn aggregates and evaluated motility in 2-day-old adult
animals. To inhibit autophagic flux, we added 10,000 μM chloroquine
(Sigma-Aldrich-Merck) 24 h before scoring the number of inclusion
bodies. Worms were incubated at 20 °C, under agitation, until they
reached young adulthood or the 2-day-old adult stage.
2.5. In vivo scoring of polyQ aggregates in muscle cells
Expression of the 40Q::YFP transgene produces aggregates of
polyQs in an age-dependent manner, which can be followed using a
dissecting microscope equipped with fluorescence. At least twenty
young adult were analysed for each genotype and each independent
experiment for each condition using an M165FC Leica dissecting mi-
croscope (Leica, Wetzlar, Germany). To analyse the impact of met-
formin and salycilate treatment on already-formed aggregates, we as-
sessed this possible effect in ten 2-day-old adults, repeating the analysis
in three independent experiments.
2.6. Motility assay
To evaluate the fitness of animals with different genotypes and
treatments, we evaluated motility in worms using thrashing assys, a
measure of fitness which correlate with healthspan in C. elegans
[35,36]. To asses the motility capacity of worms expressing the
40Q::YFP transgene, we counted the number of thrashes per treated
animal for 30 s and we extrapolated the average data to represent
thrashes per minute. Before scoring, each animal was aclimatted in M9
medium for 30 s. We analysed at least 30 untreated/treated animals
(L4, young adult and 2-day-old adult depending on the experiment) per
condition, and we performed each experiment three times to obtain
reproducible values.
2.7. Evaluation of the touch response
The aggregation of polyQ-containing proteins in mechanosensory
neurons in the 112Q::TdTomato worms, induces a touch response
dysfunction. The touch response of at least 40 young adult animals was
analysed by gently passing an eyelash mounted on a toothpick on the
posterior part of the animals as described elsewhere [9]. Each animal
was touched 10 times and we represented the percentage of times that
the animal responded. Each assay was repeated at least three times. The
touch response phenotype was scored using an MS5 dissecting micro-
scope (Leica).
2.8. In vivo scoring of α-synuclein aggregates
In contrast to worms expressing polyQs in muscle cells, animals
expressing the α-synuclein::YFP transgene, show aggregation in old
worms (2-day-old adult animals or older). Therefore, we treated young
adult animals, which did not show aggregation of this molecule yet, and
we evaluated the number of α-syn aggregates in the area located be-
tween the two pharyngeal bulbs, in 2-day-old adult animals as de-
scribed elsewhere [34]. We used a DM2500 (Leica) vertical fluores-
cence microscope for scoring. We analysed 30 untreated/treated 2-day-
old adult animals in total per condition and we reproduced each ex-
periment at least three times.
2.9. Fluorescent microscopy imaging
Images were collected using a Leica SP5 confocal microscope
(Leica). Live animals were mounted onto 2% agar pads and anaes-
thetized with a drop of 0.05 M sodium azide.
2.10. Immunoblotting
For polyQ protein quantification, treated young adult animals were
washed with M9 1X buffer before lysing the samples with RIPA buffer
(Invitrogen, Carlsbad, CA, USA) and proteinase inhibitors cocktail
(Complete, Roche, Basel, Switzerland). Samples were boiled at 100 °C
for 10 min containing 4X SDS sample loading buffer. Protein extracts
were separated by 8% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to polyvinylidene di-
fluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA)
by semi-dry blotting (Trans-Blot Turbo, Bio-Rad). Blocking was done
with 3% milk, according to the specification of the following primary
antibodies: mouse anti-polyQ (1:1000, Sigma Ref. #P1874) and mouse
anti-actin (1:500, Invitrogen ref. #MA5−11869) to normalize values.
Primary antibodies were incubated overnight at 4 °C degrees with
shaking. We used the secondary antibody anti-mouse conjugated to
HRP (1:10000, Santa Cruz ref. #SC-2005, Santa Cruz Biotechnology,
Dallas, TX, USA) to develop immunoblots. Images were obtained using
Amersham Imager 600 and enhanced chemiluminescent (ECL) detec-
tion (GE Healthcare, Chicago, IL, USA). Quantification values were
obtained using the Image J software.
2.11. Statistical analysis
Binomial logistic regression was used to study the synergistic effect
of metformin treatment on the number of touch responses out of 10
trials. Also, due to the discrete nature of the variable, we carried out
negative binomial logistic regression to study the influences of these
drugs on the dynamics of aggregation. Thrashing measurements were
analysed using linear regression models given its quantitative nature. R
software (version 3.5.1) was used to perform the statistical analyses.
The results are presented as Odds Ratio (OR) or Estimate, lower and
upper confidence interval (CI95 %), and p-value to indicate the sig-
nificance of the data. The experimenter was blinded to genotype and
treatment in all experiments through the work.
3. Results and discussion
3.1. Metformin and salicylate synergise to reduce polyglutamine-induced
toxicity
Aspirin and derivatives (such as salicylate) and metformin act
pleiotropically to activate many different targets [37,38]. Moreover,
these substances have side effects when used chronically, e.g., weight
loss (metformin [39]) or gastrointestinal bleeding (aspirin [40]).
However, both substances have been shown to synergise to improve
insulin sensitivity [23]. Since synergic action requires lower doses of
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both substances, it may reduce the side effects of these drugs, probably
through activation of a unique pathway. In this regard, metformin and
salicylate have been shown to indirectly and directly activate AMPK,
respectively [41,42]. However, both substances are also able to mod-
ulate the function of many other targets and cellular processes. For
example, metformin inhibits mitochondrial complex I, which in turn
raises AMP/ATP levels, thus activating AMPKγ, which activates
AMPKα. However, this substance is also able to inhibit mTOR and in-
crease insulin levels [43]. This pleiotropic behaviour applies to salicy-
late as well, which not only allosterically activates AMPK through
binding to AMPKβ [41] but also modulates many other targets [44].
Therefore, the rationale of our study was to investigate whether
metformin and salicylate can synergise to reduce toxicity induced by
polyQs expression in vivo, by reducing their concentrations to a limit
where other targets are unaffected. We also aimed to find out the me-
chanism behind AMPK-specific reduction of polyQ toxicity. To achieve
this goal, we used a C. elegans model of neuronal toxicity, carrying a
transgene that induced expression of 112Q fused to the dimeric fluor-
escent protein TdTomato (TdTom) in mechanosensory neurons, which
in turn impaired their function (Fig. 1A) [16]. Therefore, we could
assay mechanosensation in these worms by gently touching their tails
with an eyelash mounted in a toothpick [16]. These animals normally
respond only 25 % of the time, while wild type worms do it 7 out of 10
times (OR = 6.71, CI95 %[5.19, 8.73], p< 0.001) (Fig. 1B) [16]. We
cultured worms in many different concentrations of both drugs sepa-
rately and together to identify synergistic doses (data not shown).
Firstly, we observed that treating the worms with 50 μM salicylate
alone rescued neuronal function (OR = 2.18, CI95 %[1.83, 2.59],
p< 0.001), to the same degree as 2000 μM metformin (Fig. 1B), as we
had reported before [15,16].
Secondly, we found that 150 μM metformin and 5 μM salicylate
together was the minimal dose to synergistically rescue neuronal
function in polyQ worms (Estimate = 0.55, CI95 %[1.20, 2.53], p =
0.004) (Supplemental Fig. S1), to the level of polyQ-stressed worms
treated with either 2000 μM metformin or 50 μM salicylate alone (OR
= 1.86, CI95 %[1.46, 2.36], p< 0.001) (Fig. 1B). In contrast to the
dual combination (150 μM metformin/5 μM salicylate), both com-
pounds were ineffective separately (OR = 1.16, CI95 %[0.91, 1.48], p
= 0.214; OR = 0.92, CI95 %[0.76, 1.11], p = 0.374) respectively)
(Fig. 1B). Pharmacological assays with 2000 μM metformin, 50 μM
salicylate and combination of both (150 μMmetformin/5 μM salicylate)
improved neuronal mechanosensation in 112Q::TdTom worms while
showed an innocuous effect in wild type animals (OR = 0.92, CI95
%[0.65, 1.31], p = 0.658; OR = 0.91, CI95 %[0.64, 1.29], p = 0.595;
OR = 0.97, CI95 %[0.68, 1.37], p = 0.859, respectively), suggesting
that this treatment specifically reduces polyQ neuronal stress in worms
(Fig. 1B). As we have used ten-fold lower doses of each drug, this may
reduce the chance of activation of undesired side targets, minimizing
potential side effect of this treatment, which is relevant for future
therapy in humans.
To obtain insight into the mechanisms of neuroprotection by met-
formin/salicylate, we sought to test whether these drugs altered the
dynamics of polyQ aggregation. If that was the case, this would suggest
that pathways of misfolded protein clearance were involved in neuro-
protection by metformin/salicylate treatment. To test this hypothesis,
we used worms that expressed 40 CAG repeats in frame with the yellow
fluorescence protein (40Q::YFP) in muscle cells, which showed age-
dependent aggregation of polyQs (Fig. 1A) [8]. In agreement with
previous work [16] treatment with 2000 μM metformin (positive con-
trol) drastically reduced the number of polyQ aggregates compared to
untreated young adult animals (OR = 0.80, CI95 % [0.69, 0.90],
p< 0.001) (Fig. 1C). As expected, culturing 40Q worms in 50 μM sal-
icylate also resulted in reduced number of aggregates (OR = 0.81, CI95
% [0.70, 0.91], p = 0.001) (Fig. 1C). Finally, culturing 40Q::YFP
worms in 150 μM metformin plus 5 μM salicylate had a synergistic
effect and significantly decreased the number of aggregates (OR =
0.80, CI95 % [0.71, 0.92], p = 0.001) (Fig. 1C and 1D), in contrast to
worms treated with either 150 μM metformin (OR = 0.97, CI95 %
[0.85, 1.09], p = 0.574) or 5 μM salicylate (OR = 0.98, CI95 % [0.86,
1.11], p = 0.749) alone (Fig. 1C). Pharmacological treatements did not
affect the total expression of polyQ protein (Fig. 1E, F), suggesting that
the activity of the unc-54 promoter, which drives the expression of the
40Q::YFP transgene, was unaltered by these compounds.
Reduction of polyQ aggregation may not be followed by better
function of the muscle cells of the worms. To check whether treated
animals showed better fitness we used thrashing assays. These assays
consist of counting how many “thrashes”, or body bends, do the animals
in liquid to avoid being pulled down by gravity [45]. It has been shown
Fig. 1. Metformin and salicylate act synergistically to reduce polyQ aggregation and restore neuronal function. A) Models of polyQ toxicity used for assessing the
synergistic effect of metformin and salicylate. Model 1 (112Q:TdTom) is a model of neuronal toxicity, carrying a transgene that induces expression of 112Q fused to
TdTomato fluorescent dimeric protein in mechanosensory neurons under the control of mec-3 promoter. Model 2 (40Q::YFP) is a model of polyQ muscle aggregation
that carries a transgene that expresses 40Q fused to YFP (Yellow Fluorescent Protein), in muscle cells under the control of unc-54 promoter. B). The expression of
112Q:TdTom in mechanosensory neurons induces impairment of neuronal function compared to animals that do not have the transgene (OR = 6.71, CI95 %[5.19,
8.73], p<0.001). Treatment with 2000 μMmetformin and 50 μM salycilate separately rescue neuronal function in 112Q young adult animals compared to untreated
animals (OR = 2.59, CI95 %[2.33, 2.88], p<0.001; OR = 2.18, CI95 %[1.83, 2.60], p< 0.001; respectively). Lower doses of metformin/salycilate in combination
(150 μM and 5 μM respectively) rescue neuronal function synergistically in 112Q young adult animals (OR = 1.86, CI95 %[1.46, 2.36], p<0.001), while single
treatments do not modify the touch response compared with 112Q control (OR = 1.16, CI95 %[0.91, 1.48], p = 0.214; OR = 0.92, CI95 %[0.76, 1.11], p = 0.374
respectively). All effective single and dual treatments do not change mechanosensorial function in wild type young adult animals (OR = 0.92, CI95 %[0.65, 1.31], p
= 0.658; OR = 0.91, CI95 %[0.64, 1.29], p = 0.595; OR = 0.97, CI95 %[0.68, 1.37], p = 0.859 respectively). C) Single treatment with 2000 μM metformin and 50
μM salicylate reduce polyQ aggregation in 40Q young adult animals (OR = 0.79, CI95 %[0.69, 0.90], p<0.001; OR = 0.80, CI95 %[0.70, 0.91], p = 0.001,
respectively). Synergistic combination (150 μM metformin/ 5 μM salicylate) decreases polyQ aggregation at the same level of high dose of drugs (OR = 0.81, CI95
%[0.71, 0.92], p = 0.001). D) Representative photographs from untreated and treated (150 μM metformin/5 μM salycylate) 40Q::YFP young adult animals show a
different polyQ aggregation pattern in body wall muscles. E) Inmunoblot of the total levels of polyQ::YFP proteins. Proteins weredetected using a mouse anti-polyQ
primary antibody conjugated to HRP (1:10000, Santa Cruz ref. #SC-2005). Samples were obtained from untreated and treated 40Q young adult animals (2000 μM
metformin, 50 μM salicylate and 150 μM metf/5 μM sal combination) as described in Materials and Methods. F) Levels of polyQ::YFP expression were quantified by
Image J software and values were normalized to untreated 40Q::YFP worms. G) Metformin and salicylate induce rescue of motor function in 40Q young adult
animals. 40Q young adult animals show a significant motor defect compared to wild type young adult animals (whithout the polyQ transgene) (Estimate = 54.73;
CI95 %[44.42, 65.05], p< 0.001). Culturing worms in high doses of the drugs (2000 μM metformin and 50 μM salicylate) improve motility in 40Q young adults
compared with untreated animals (Estimate = 17.66, CI95 %[8.72, 26.60], p< 0.001; Estimate = 23.70, CI95 %[14.13, 33.27], p<0.001, respectively), while low
doses separately (150 μM metformin or 5 μM salicylate) do not modify the motor phenotype (Estimate = 3.92, CI95 %[-5.78, 13.63], p = 0.427; Estimate = -2.02,
CI95 %[-11.73, 7.69], p = 0.683 respectively). Dual treatment with low doses of metformin (150 μM) and salycilate (5 μM) rescues motility impairment in 40Q
young adult animals significantly (Estimate = 22.20, CI95 %[12.63, 31.77], p<0.001). Neither of single and mix treatments improve motility phenotype in wild
type background. PolyQ aggregation analysis shows Odds Ratio (OR), lower and upper confidence interval 95 % (CI95 %) and p-value to indicate the significance of
the data. For thrashing analysis, OR value is changed by Estimate value according to the type of the variable. At least thirty animals were tested and three
independent experiments were performed in each case. Scale bar represents: 50 μm.
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that animals performing better thrashing show also better lifespan and
overall healthspan [36]. Moreover, worm models expressing polyQ-
containing proteins in muscle cells have reduced thrashing in liquid
[46,47]. As we expected, we observed that worms expressing polyQs in
muscle cells showed reduced thrashing activity (Estimate = 54.73;
CI95 %[44.42, 65.05], p< 0.001) (Fig. 1G). Interestingly, treated
worms (with metformin 2000 μM, salicylate 50 μM and synergistic
combination of both) had a better motility capacity than untreated
animals (Estimate = 17.66, CI95 %[8.72, 26.60], p< 0.001; Estimate
= 23.70, CI95 %[14.13, 33.27], p< 0.001; Estimate = 22.20, CI95
%[12.63, 31.77], p< 0.001, respectively) (Fig. 1G). In contrast, treated
40Q::YFP young adult animals with low dose of drugs (metformin or
salicylate) alone did not show statistical differences in their motility
capacity in comparison to untreated animals (Estimate = 3.92, CI95
%[-5.78, 13.63], p = 0.427; Estimate = -2.02, CI95 %[-11.73, 7.69], p
= 0.683 respectively) (Fig. 1G). In agreement with the touch response
assays, treated and untreated wild type young adult animals showed the
same motility capacity values, suggesting that these drugs specifically
reduce polyQ stress in muscle cells (Fig. 1G).
An interesting question is whether protein aggregates can be re-
moved, once they have been formed. To evaluate whether metformin
and salicylate are protective in worms containing already aggregates,
we treated 40Q::YFP young adult animals and we analysed the number
of polyQ aggregates when they reached the 2-day-old adult stage. We
did not observe differences between untreated/treated animals with
2000 μM metformin, 50 μM salicylate and synergistic combination of
both (150 μM metf/5 sal μM) (OR = 0.98, CI95 %[0.91, 1.06], p =
0.661; OR = 0.98, CI95 %[0.91, 1.06], p = 0.616; OR = 0.97, CI95
%[0.90, 1.04], p = 0.355, respectively) (Supplemental Fig. S2).
Therefore, the therapeutic effect of these drugs prevents or delays ag-
gregation formation from early stages, but it is ineffective once the
aggregates have been formed.
3.2. Synergistic reduction of polyQ aggregation requires AMPK catalytic
function
Metformin and salicylate are well-known AMPK activators, though
both drugs are pleiotropic so they can modulate the function of a wide
range of targets (see for example [25–29]) show undesirable side effects
[45,46]. Therefore, Next, we sought to test whether a reduction in the
number of aggregates in 40Q::YFP worms treated with metformin and
salicylate required AMPK function. To do so, we analysed worms de-
fective of the only catalytic subunit of AMPK that affected the lifespan
and health in C. elegans (aak-2/AMPKα2) [48]. Analysis of 40Q; aak-
2(ok524) young adults showed a statistically significant increase in the
number of polyQ aggregates in comparison to wild type animals (OR =
1.26, CI95 % [1.19, 1.33], p< 0.001) (Fig. 2C). Moreover, protection
by metformin and salicylate was suppressed in 40Q; aak-2(ok524)
worms (OR = 0.98, CI95 % [0.933, 1.037], p = 0.541) (Fig. 2C). In
addition, aak-2 loss of function induced an aggravation of the motor
defect in the young adult animals compared to 40Q controls (Estimate
= -43.93, CI95 %[-48.13, -39.74], p< 0.001) (Fig. 2D) and the moti-
lity capacity of treated 40Q; aak-2(ok524) young adults was not rescued
by the treatment with the combination of metformin and salicylate
(Estimate = -3.80, CI95 %[-8.03, 0.43], p = 0.077) (Fig. 2D). There-
fore, and in agreement with previous results [16,20], these data show
that the catalytic subunit of AMPK is required for the protective effect
of these drugs. The reduction of polyQ aggregates by metformin and
salicylate, and the exclusive requirement of an active AMPK function is
relevant from a therapeutic point of view, since by using low doses of
these chemicals, it could prevent the activationof other targets, and
therefore it could reduce undesired pharmacological effects associated
with these drugs.
3.3. The mechanism of reduction of polyQ aggregation by metformin and
salicylate involves the function of the regulatory AMPKβ2
To investigate the mechanistic aspects of metformin/salicylate sy-
nergism, we also tested whether the regulatory subunit AMPKβ, which
could respond to direct binding of salicylate [41], was also required for
the induced reduction of polyQ aggregates by these drugs. The genome
of C. elegans encodes two isoforms of AMPKβ, aakb-1, and aakb-2. Since
there was no available strain with a mutant allele of aakb-1 in the CGC
worm collection, we generated the aakb-1(vlt18) mutant using CRISPR/
Cas9 (Fig. 2A). To do so we designed two guide RNAs (gRNAs or
crRNAs) against the first and last exon of aakb-1 (Fig. 2A), so the in-
jection of ribonucleoproteins carrying both gRNAs would delete most of
the coding region. Although we were not able to isolate a mutant that
had a deletion between these exons, we isolated worms with vlt18, a
deletion that covered most of the gene sequence (Fig. 2A). This deletion
includes the donor splicing site of the first exon, so aakb-1 is likely
unable to splice correctly (Fig. 2A). Even if the gene was correctly
spliced and all coding sequences remained in-frame, it would produce a
truncated protein (Fig. 2B) that would lack a large part of the N-
terminal region, including half of the carbohydrate-binding-domain
(CBM) (Fig. 2B), which is essential for salicylate activation of AMPK
function [19].
Analysis of 40Q; aakb-1(vlt18) young adults showed a statistically
significant increase in the number of polyQ aggregates (OR = 1.17,
CI95 % [1.11,1.24], p< 0.001) (Fig. 2C). However, the effect of loss-of-
function of the catalityc subunit (aak-2) was stronger than the one
produced by the aakb-1 mutation, on polyQ aggregation (OR = 1.07,
CI95 % [1.02, 1.13], p = 0.008) (Fig. 2C). This suggests that, although
the function of the regulatory subunit (AMPKβ1) was important, com-
plete removal of AMPKα catalytic subunit resulted in higher polyQ
aggregation.
Aside from the impact of removing either of AMPK subunits on
polyQ aggregation, metformin/salicylate treatment of these mutants
showed remarkable differences. While removal of aakb-1 did not
eliminate protection from polyQ toxicity by these drugs (OR = 0.81,
CI95 % [0.76, 0.85], p< 0.001) (Fig. 2C), suppression of aak-2 com-
pletely blocked reduction of polyQ aggregation by metformin and sal-
icylate (OR = 0.98, CI95 % [0.93, 1.04], p = 0.54) (Fig. 2C). In regard
to the motor phenotype, ablation of aakb-1 showed a very small ten-
dency to fall, compared with the drastic drop of aak-2mutants, that was
not statistically different from wild type worms (Estimate = -4.13, CI95
%[-8.33, 0.06], p = 0.053 (Fig. 2D). This apparent disconnection be-
tween the aggregation of polyQ-phenotype and motor behaviour may
be due to the mild aggregation phenotype presented in the aakb-1
mutants. In any case, metformin and salicylate were able to rescue
motility in aakb-1(vlt18) (Estimate = 12.13, CI95 %[7.31, 16.95],
p< 0.001) (Fig. 2D) in these animals. Taken all together, these data
suggest that, although aakb-1 is required to modulate polyQ aggrega-
tion, it does not participate of the synergistic effect of metformin and
salicylate on protein homeostasis.
As aakb-1 is not involved in the synergistic activation of AMPK by
metformin and salicylate, we sought to test whether the gene encoding
the second isoform of AMPKβ present in C. elegans (aakb-2) could play a
role in this process. To do so, we used initially the aakb-2(rr88) loss of
function mutants. However, this strain had strong sterility (data not
shown) which prevented our analysis. Therefore, we took advantage of
the RNAi technology to suppress aakb-2 function, in both wild type and
aakb-1 mutants expressing polyQs in muscle cells (40Q::YFP worms).
Knocking down aakb-2 by RNAi in wild type 40Q::YFP animals slightly
increased polyQ aggregation compared to the controls (OR = 1.174,
CI95 % [1.07, 1.29], p = 0.001), though not to the level of the struc-
tural mutant aakb-1 (OR = 1.207, CI95 % [1.107, 1.316], p< 0.001)
(Fig. 2E). This milder enhancement of polyQ aggregation may be due to
a partial suppression of aakb-2 by RNAi, but it may also be due to a less
relevant role of this isoform in regulating protein homeostasis.
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Although aakb-2(RNAi) worms showed lower number of polyQ ag-
gregates than aakb-1(vlt18) mutants, aakb-2(RNAi) animals did not
respond to metformin/salicylate treatment (OR = 0.92 CI95 % [0.84,
1.01], p = 0.07), which suggests that its function is important for the
effect of these drugs (Fig. 2E). Double ablated animals (aakb-1(vlt18);
aakb-2(RNAi)) showed the highest increase of polyQ aggregation, and
they completely failed to respond to metformin/salicylate (OR = 1.063
CI95 % [0.99, 1.14], p = 0.10) (Fig. 2E). These results suggest that only
aakb-2 is required for the action of metformin/salicylate to reduce
polyQ aggregation, although both isoforms are essential for appropriate
protein homeostasis in C. elegans.
We then analysed the motility capacity of aakb-2(RNAi) in
(caption on next page)
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untreated/treated worms. In this context, untreated aakb-2(RNAi) an-
imals showed a lower number of thrashes compared to 40Q::YFP
(Estimate = -16.53, CI95 %[-20.88, -12.18], p< 0.001) (Fig. 2F),
suggesting that increased polyQ aggregation translates into worse
motor performance. As we expected, reduction of aakb-2 expression
blocked the rescue induced by metformin/salicylate combined treat-
ment, observed in the wild type worms expressing polyQs (Estimate =
1.73, CI95 %[-1.45, 4.91], p = 0.28) (Fig. 2F). Hence, the aakb-2 iso-
form is required for the action of metformin and salicylate to restore
healthspan disrupted by expression of polyQ-containing proteins in C.
elegans.
3.4. Neuronal protection of metformin and salicylate is dependent on AMPK
functional subunits
It has been shown before that AMPK function is important for ap-
propriate mechanosensation in C. elegans neurons stressed by polyQs
[9,12,13,15,16]. In agreement with these results, 112Q::TdTom worms
showed reduced touch response when we introduced a mutant allele of
AMPKα, aak-2(ok524), (OR = 0.39, CI95 % [0.27, 0.56], p< 0.001)
(Fig. 2G). Analysis of wild type 112Q::TdTom worms treated with
metformin/salicylate showed that the animals recovered neuronal
function compared to untreated animals (OR = 1.73, CI95 % [1.29,
2.33], p< 0.001) (Fig. 2G). However, this recovery was absent in
112Q; aak-2(ok524) mutant worms (OR = 1.14, CI95 % [0.76, 1.71], p
= 0.53) (Fig. 2G). Interestingly, the ablation of aakb-1/AMPKβ1 also
drastically reduced the touch response of polyQ-stressed animals (OR=
0.36, CI95 % [0.25, 0.52], p< 0.001) (Fig. 2G). This result suggests
that both AMPK subunits (aak-2 and aakb-1) are important for protein
homeostasis in neurons, as it happens in muscle cells (Fig. 2C-F). aakb-
1(vlt18) mutant worms responded well to metformin/salicylate treat-
ment (OR = 2.17, CI95 % [1.48, 3.21], p< 0.001) (Fig. 2G), in con-
trast to the null response of animals defective of aak-2 (OR = 1.14,
CI95 % [0.76, 1.71], p = 0.53) (Fig. 2G). These results suggest that
aakb-1 plays a role in neuroprotection, although it is dispensable for the
effects of metformin and salicylate to reduce polyQ-induced neuronal
toxicity.
3.5. The beneficial effect of metformin/salicylate on polyQ aggregation is
mediated through autophagy
We have demonstrated that metformin/salicylate synergistically
reduce polyQ aggregation and toxicity in an AMPK-dependent manner.
Since this enzyme is a direct activator of autophagy (reviewed by Li and
Chen [49]), we sought to investigate whether autophagy was involved
in the reduction of polyQ toxicity by these drugs. To investigate this
possibility, we disrupted the autophagy pathway in metformin/salicy-
late treated animals, hypothesizing that the beneficial effect of the
drugs would be lost. We used two approaches: 1) inhibition of the au-
tophagic flux with chloroquine to block autophagosome-lysosome fu-
sion and activity [50]; and 2) disruption of autophagy-related genes by
knocking down LGG-1/LC3, ATG-18/ATG-18 and BEC-1/ATG-6, using
RNAi technology [51,52]. In constrast to wild type animals, where
metformin/salicylate reduced aggregation (OR = 0.67, CI95 % [0.58,
0.78], p< 0.001) (Fig. 3A), preventing autophagy with chloroquine
completely blocked reduction of polyQ aggregation by metformin/sal-
icylate, so the worms treated with all three substances (metformin/
salicylate/chloroquine) had the same aggregation pattern as untreated
worms (OR = 1.10, CI95 % [0.95, 1.27], p = 0.177) (Fig. 3A). All
groups of animals treated with chloroquine (with and without met-
formin/salicylate) showed no statistically significant different number
of polyQ aggregates (OR = 1.02, CI95 %[0.89, 1.17], p = 0.739)
(Fig. 3A). From a functional point of view, we observed that chlor-
oquine did not show a motility rescue in metformin/salicylate treated
worms, compared to animals cultured with chloroquine alone (Estimate
= 0.67, CI95 %[-7.88, 9.21], p = 0.874) or with untreated control L4
animals (Estimate = -1.47, CI95 %[-11.17, 8.24], p = 0.763) (Fig. 3B).
These results confirmed our previous observation that inhibition of
autophagic flux in polyQ-stressed worms reduced the benefit of met-
formin treatment [16].
It is known that inactivation of autophagy by silencing several es-
sential genes, such as atg-18 and bec-1, modifies aggregation pattern in
40Q animals [53]. In addition, it has been shown that aspirin, a syn-
thetic derivative of salicylate, causes activation of autophagy through
lgg-1 in C. elegans [54]. Therefore, we tested metformin/salicylate ef-
fects in 40Q::YFP animals depleted of LGG-1, ATG-18 and BEC-1 (lgg-
1(RNAi), atg-18(RNAi) and bec-1(RNAi) worms). First, we observed
that after 24 h of feeding 40Q L4 animals with RNAi against the atg-18,
bec-1 and lgg-1 genes, silenced 40Q L4 animals showed an increment of
polyQ aggregation pattern, compared with wild type 40Q animals (OR
= 1.26, CI95 %[1.13, 1.41], p< 0.001; OR = 1.25, CI95 %[1.12,
1.39], p< 0.001; OR = 1.28, CI95 %[1.15, 1.43], p< 0.001, respec-
tively) (Fig. 3C). We also observed that animals silenced by RNAi (atg-
18, bec-1 and lgg-1) were unresponsive to the beneficial effect of
Fig. 2. The beneficial synergistic effect of metformin and salicylate on polyQ aggregation requires AMPK activity. A) Diagram of the genomic locus encoding aakb-1
and the position of the guide RNAs (gRNA) used to produce a knock out of the gene by CRISPR/Cas9. Green boxes represent exons; thin black inclined lines indicate
introns. The red scissors represent the Cas9 nuclease bound to the gRNA. The red lines indicate the place of probable cut within the gene. The result of deleting the
region between the gRNAs is shown below the genomic locus of aakb-1 (1 kb length). This deletion includes the donor splicing site of the first exon (in yellow), so
aakb-1(vlt18) is likely unable to splice correctly. B) Diagram representing the protein AAKB-1/AMPKβ1 and its functional domains. The truncated locus, after CRISPR
treatment, may produce a truncated protein, lacking part of the CBM C) The graph represents the number of polyQ aggregates in several young adults of the following
strains: 40Q, 40Q; aak-2(ok524) and 40Q; aakb-1(vlt18) treated with metformin 150 μM and salicylate 5 μM, or with vehicle (H2O). Reduction of polyQ aggregation,
induced by synergistic metformin and salicylate treatment, depends on aak-2/AMPKα (OR= 0.98, CI95 % [0.933, 1.037], p = 0.541), while aakb-1/AMPKβ1 (OR=
0.81, CI95 % [0.76, 0.85], p<0.001) is not implicated. D) Graph showing the results of the thrashing assays in the aakb-1(vlt18) and aak-2(ok524) mutants into a
polyQ toxicity context. The ablation of aakb-1 does not modify motility of 40Q young adult animals (Estimate = -4.13, CI95 %[-8.30, 0.06], p = 0.053), in contrast
to aak-2 ablated animals (Estimate = -43.93, CI95 %[-48.13, -39.74], p< 0.001). The protector role of the synergistic treatment is blocked in aak-2 ablated animals
(Estimate = -3.80, CI95 %[-8.03, 0.43], p = 0.077), while aakb-1 mutants did not modify the effect of the drugs (Estimate = 12.13, CI95 %[7.31, 16.95],
p< 0.001). E) Graph representing the average number of polyQ aggregates in treated (150 μM metformin/5 μM salycilate) and untreated 40Q, 40Q; aakb-1(vlt18),
40Q; aakb-2(RNAi) and double mutants L4 animals. Both subunits, AAKB-1 and AAKB-2, modulate polyQ aggregation, however only ablation of aakb-2 is essential for
the response to the synergistic effect of metformin and salicylate in muscle aggregation. Double mutants aakb-1; aakb-2 failed to rescue polyQ aggregation phenotype
upon metformin/salicylate treratment compared to untreated double mutants (OR = 1.06, CI95 %[0.99, 1.14], p = 0.10). F) Graph showing the data regarding the
fitness of the worms. Ablation of aakb-2 by RNAi silencing disrupts motility capacity in L4 40Q animals (Estimate = -16.53, CI95 %[-20.88, -12.18], p<0.001).
Motility rescue by 150 μM metformin plus 5 μM salicylate is observed in 40Q L4 animals (Estimate = 13.73, CI95 %[9.16, 18.31], p<0.001), while the beneficial
effect is supressed in ablated aakb-2 L4 animals (Estimate = 1.73, CI95 %[-1.46, 4.91], p = 0.28). G) Mechanosensorial function is measured by percentage of touch
response in 112Q::TdTom (denoted as 112Q), 112Q; aak-2(ok524) and 112Q; aakb-1(vlt18) after treatment or not with metformin 150 μM and salicylate 5 μM.
Defective animals of aak-2 respond worse to metformin/salicylate treatment (OR= 1.14, CI95 % [0.76, 1.71], p = 0.53) while null aakb-1 animals show a significant
response (OR = 2.17, CI95 % [1.48, 3.21], p< 0.001). PolyQ aggregation analysis show Odds Ratio (OR), lower and upper confidence interval 95 % (CI95 %) and p-
value to indicate the significance of the data. For thrashing and touch analysis, OR value is changed by Estimate value according to the type of the variable At least
thirty animals were tested and experiments were performed three independent times.
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metformin and salicylate, since the number of polyQ aggregates were
statistically similar to untreated silenced animals (OR = 0.99, CI95
%[0.89, 1.09], p = 0.792; OR = 1.05, CI95 %[0.94, 1.16], p = 0.389;
OR = 1.02, CI95 %[0.92, 1.12], p = 0.775, respectively) (Fig. 3C). In
agreement with our previous results, treated silenced worms did not
show a different motility pattern compared with untreated silenced
animals for atg-18, bec-1 and lgg-1 (Estimate = -7.73, CI95 %[-21.90,
6.44], p = 0.273; Estimate = 0.40, CI95 %[-10.93, 11.73], p = 0.943;
Estimate = 2.13, CI95 %[-7.50, 11.76], p = 0.653, respectively)
(Fig. 3D). These results are consistent with previous work from other
authors, who showed that metformin could extend lifespan in C. elegans
by activation of the lysosomal pathway, in an lgg-1-dependent manner
[55]. Altogether, these results show that the autophagy flow is required
for the synergistic effect of metformin/salicylate on polyQ aggregation
and motility. Although is tempting to speculate that AMPK activation,
by metformin and salicylate, is inducing autophagy, which in turns
reduces polyQ aggregation and enhances motility, we cannot rule out
the possibility that AMPK activation and autophagy may run in parallel.
3.6. α-synuclein aggregation pattern is rescued by AMPK activators
We sought to test whether AMPK activators could influence the
toxicity induced by α-synuclein, to broaden the range of diseases in
which these compounds could be useful. To do so, we used a well-
known C. elegans model of Parkinson's disease, the strain NL5901,
which expresses α-synuclein::YFP in muscle cells (α-syn from now on)
[31]. The expression of this construct produces aggregation of this
peptide in old adult worms (from 2-day-old adult animals onwards),
which we could analyse using a fluorescence microscope. Hence, we
treated young adult α-syn::YFP animals, which do not show yet ag-
gregates, with 2000 μM metformin, and then analysed 2-day-old adult
stage. This analysis showed that these worms had a reduction of α-syn
aggregates compared to untreated animals (OR = 0.55, CI95 %[0.45,
0.69], p< 0.001) (Fig. 4A). Treating these animals with 50 μM sali-
cylate showed a similar result (OR = 0.61, CI95 %[0.49, 0.75],
p< 0.001) (Fig. 4A). As we expected, we could not observe differences
between animals treated just with low doses of metformin or salicylate
(150 μM metformin or 5 μM salicylate), and untreated worms (OR =
0.94, CI95 %[0.76, 1.16], p = 0.545; OR = 1.05, CI95 %[0.85, 1.3], p
= 0.679, respectively) (Fig. 4A). However, synergistic combination of
both reduced significantly α-syn aggregates in muscle cells compared to
control animals (OR = 0.63, CI95 %[0.50, 0.78], p< 0.001) (Fig. 4A
and B).
In parallel, we tested whether drug treatment improved health
condition of α-syn::YFP animals by conducting the thrashing assay. In
this case, treated 2-day-old adult worms with 2000 μMmetformin or 50
μM salicylate separately showed an improvement of motility capacity
compared to untreated animals (Estimate = 12.60, CI95 %[4.74,
20.47], p = 0.002; Estimate = 13.47, CI95 %[5.60, 21.33], p = 0.001,
respectively) (Fig. 4C). In contrast, single low dose of drugs (metformin
150 μM and salicylate 5 μM) showed to be ineffective (Estimate =
0.733, CI95 %[-7.13, 8.60], p = 0.854; Estimate = -0.93, CI95
%[-8.80, 6.93], p = 0.815, respectively), while combination of both,
increased significalty motility of animals compared to untreated α-sy-
n::YFP 2-day-old adult animals (Estimate = 12.60, CI95 %[4.74,
20.47], p = 0.002) (Fig. 4C). These results suggest that metformin,
salicylate and synergistic combination of them are able to reduce pro-
tein aggregation from other toxic species, and restore healthspan.
4. Conclusions
Our study shows for the first time that synergistic activation of
Fig. 3. Autophagy is required to induce the
beneficial synergistic effect of metformin and
salicylate on polyQ aggregation. A) The
blocking effect of chloroquine on lysosomal
flow suppresses protection by metformin/sali-
cylate in L4 treated larvae with 10 mM chlor-
oquine (OR = 1.10, CI95 % [0.95, 1.27], p =
0.177). B) Metformin and salycilate together
improve motility of 40Q L4 animals (Estimate
= 21.73, CI95 %[12.03, 31.44], p<0.001).
After chloroquine treatment, 40Q L4 animals
treated with the synergistic combination of
drugs failed to rescue motility (Estimate =
-1.47, CI95 %[-11.17, 8.24], p = 0.763). C)
The reduction of the function of atg-18, bec-1
and lgg-1 increase polyQ aggregation in muscle
cells (OR = 1.26, CI95 %[1.13, 1.41],
p< 0.001; OR = 1.25, CI95 %[1.12, 1.39],
p< 0.001; OR = 1.28, CI95 %[1.15, 1.43],
p< 0.001, respectively). RNAi treatment of
lgg-1, atg-18 and bec-1 supresses the protective
effect of the dual treatment (150 μM met-
formin/5 μM salycilate) compared to control
40Q L4 animals (OR = 0.99, CI95 %[0.89,
1.09], p = 0.792; OR = 1.05, CI95 %[0.94,
1.16], p = 0.389; OR = 1.02, CI95 %[0.92,
1.12], p = 0.775, respectively). D) Knock
down of atg-18 and bec-1 does not modify
motility in 40Q L4 animals, although ablation
of lgg-1 slightly modifies the motility pheno-
type (Estimate = -14.13, CI95 %[-27,16,
-1.11], p = 0.034). Metformin/salicylate treated animals showed higher motility than control untreated animals (Estimate = 26.53, CI95 %[14.46, 38.61],
p< 0.001). Reduction of function of atg-18, bec-1 and lgg-1 avoid the protective effect of the synergic drugs over the motility phenotype (Estimate = -7.73, CI95
%[-21.90, 6.44], p = 0.273; Estimate = 0.40, CI95 %[-10.93, 11.73], p = 0.943; Estimate = 2.13, CI95 %[-7.50, 11.76], p = 0.653, respectively). PolyQ
aggregation analysis show Odds Ratio (OR), lower and upper confidence interval 95 % (CI95 %) and p-value to indicate the significance of the data. For thrashing, OR
value is changed by Estimate value according to the type of the variable At least thirty animals were tested in each case and we performed three independent
experiments.
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AMPK, using low doses of metformin and salicylate, alleviates the
neurotoxic effects of expanded polyQs and α-synuclein in vivo.
Activation of this enzyme, using metformin, has been shown to be a
magnificent strategy to treat behavioural and molecular symtopms in
diferent murine models of HD. However metformin is a pleitotropic
drug, as well as is salicylate, and therefore it is expected that using them
to treat HD may produce undesired secondary effects in HD patients.
Therefore, using low doses of both drugs may prevent from activation of
unwanted targets, while activation of AMPK will be maintained to in-
duce cell protection. Moreover, we show that protection induced by
synergetic treatment with both chemicals requires autophagic flow, a
cellular process which is disrupted in animal models and patients of HD.
Both AMPK and components of the autophagy process are strongly
conserved between C. elegans and mammals, and hence it is not unfair
to hypothesise that synergistic activation of AMPK may also be pro-
tective in humans. Therefore, pre-clinical trials in murine models of HD
using combinations of both drugs are justified.
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